To assess the osteogenic potential of BCM, we monitored the expression of genes encoding bone matrix proteins such as collagen type I (Col1a1 and Col1a2) and osteopontin (also known as secreted phosphoprotein 1, Spp1), as well as genes encoding the differentiation markers, runt-related transcription factor 2 (Runx2), osteocalcin (or bone gamma-carboxyglutamate protein 2, Bglap2), bone sialoprotein (or integrin-binding sialoprotein, Ibsp), and alkaline phosphatase (Alpl) in BCM-treated ST2 cells. The gene discussed is COL1A2; the disease is blue cone monochromacy.